EV/Sales Ratio: 5.13x
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 5.13x is 37% below its 5-year average of 8.14x, near the low end of its 5-year range (4.71x–13.79x).
As of Friday, June 26, 2026. 24.85% below its 12-month average of 6.83x.
RMD EV/Sales Ratio Chart
RMD Average EV/Sales Ratio Chart
RMD Current vs Average EV/Sales Ratio Chart
RMD EV/Sales Ratio Metrics
EV/SALES RATIO
5.13x
EV/SALES RATIO AVG TTM
6.83x
EV/SALES RATIO AVG 3Y
6.82x
EV/SALES RATIO AVG 5Y
7.97x
EV/SALES RATIO AVG 10Y
7.61x
EV/SALES RATIO AVG 15Y
6.47x
EV/SALES RATIO AVG 20Y
5.80x
CURRENT VS TTM AVG
-24.85%
CURRENT VS 3Y AVG
-24.73%
CURRENT VS 5Y AVG
-35.66%
CURRENT VS 10Y AVG
-32.56%
CURRENT VS 15Y AVG
-20.74%
CURRENT VS 20Y AVG
-11.61%
RMD Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ResMed Inc. (RMD) | $28.81B | 5.13x | 6.83x | 6.82x | 7.97x |
| Biogen Inc. (BIIB)vs › | $29.82B | 3.36x | 2.83x | 3.28x | 3.56x |
| IQVIA Holdings Inc. (IQV)vs › | $31.12B | 2.75x | 2.92x | 3.24x | 3.53x |
| DexCom, Inc. (DXCM)vs › | $26.49B | 5.66x | 6.54x | 10.07x | 13.75x |
| Veeva Systems Inc. (VEEV)vs › | $25.68B | 7.37x | 12.17x | 13.24x | 15.50x |
| Medline Inc. (MDLN)vs › | $31.94B | 1.43x | 1.58x | 1.58x | 1.58x |
| Centene Corp. (CNC)vs › | $31.98B | 0.14x | 0.11x | 0.20x | 0.28x |
| Mettler-Toledo International Inc. (MTD)vs › | $25.13B | 6.70x | 7.33x | 7.49x | 8.15x |
| Zoetis Inc. (ZTS)vs › | $32.62B | 4.22x | 6.56x | 8.70x | 9.83x |
| Waters Corporation (WAT)vs › | $24.57B | 9.56x | 7.11x | 7.17x | 7.32x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/Sales Ratio FAQ
- What is the EV/Sales ratio for ResMed Inc. (RMD)?
- The EV/Sales ratio for RMD stock is 5.13x.
- Is ResMed Inc.'s EV/Sales ratio high or low?
- The EV/Sales ratio of 5.13x is 37% below its 5-year average of 8.14x, near the low end of its 5-year range (4.71x–13.79x).
- What is the TTM average EV/Sales ratio for ResMed Inc. (RMD)?
- The TTM average EV/Sales ratio for RMD stock is 6.83x.
- What is the 3Y average EV/Sales ratio for ResMed Inc. (RMD)?
- The 3Y average EV/Sales ratio for RMD stock is 6.82x.
- What is the 5Y average EV/Sales ratio for ResMed Inc. (RMD)?
- The 5Y average EV/Sales ratio for RMD stock is 7.97x.
- What is the 10Y average EV/Sales ratio for ResMed Inc. (RMD)?
- The 10Y average EV/Sales ratio for RMD stock is 7.61x.
- What is the 15Y average EV/Sales ratio for ResMed Inc. (RMD)?
- The 15Y average EV/Sales ratio for RMD stock is 6.47x.
- What is the 20Y average EV/Sales ratio for ResMed Inc. (RMD)?
- The 20Y average EV/Sales ratio for RMD stock is 5.80x.
RMD EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-25 | 5.13x |
| 2026-06-24 | 5.07x |
| 2026-06-23 | 4.93x |
| 2026-06-22 | 4.86x |
| 2026-06-18 | 4.86x |
| 2026-06-17 | 4.80x |
| 2026-06-16 | 5.00x |
| 2026-06-15 | 4.97x |
| 2026-06-12 | 5.02x |
| 2026-06-11 | 4.96x |
| 2026-06-10 | 4.99x |
| 2026-06-09 | 5.08x |
| 2026-06-08 | 4.98x |
| 2026-06-05 | 5.06x |
| 2026-06-04 | 5.01x |
| 2026-06-03 | 4.80x |
| 2026-06-02 | 4.71x |
| 2026-06-01 | 4.80x |
| 2026-05-29 | 4.91x |
| 2026-05-28 | 5.25x |
| 2026-05-27 | 5.32x |
| 2026-05-26 | 5.37x |
| 2026-05-22 | 5.38x |
| 2026-05-21 | 5.40x |
| 2026-05-20 | 5.42x |
| 2026-05-19 | 5.37x |
| 2026-05-18 | 5.27x |
| 2026-05-15 | 5.21x |
| 2026-05-14 | 5.23x |
| 2026-05-13 | 5.23x |
| 2026-05-12 | 5.26x |
| 2026-05-11 | 5.13x |
| 2026-05-08 | 5.34x |
| 2026-05-07 | 5.35x |
| 2026-05-06 | 5.42x |
| 2026-05-05 | 5.37x |
| 2026-05-04 | 5.41x |
| 2026-05-01 | 5.30x |
| 2026-04-30 | 5.53x |
| 2026-04-29 | 5.70x |
| 2026-04-28 | 5.84x |
| 2026-04-27 | 5.97x |
| 2026-04-24 | 5.91x |
| 2026-04-23 | 5.90x |
| 2026-04-22 | 5.97x |
| 2026-04-21 | 5.95x |
| 2026-04-20 | 6.08x |
| 2026-04-17 | 6.14x |
| 2026-04-16 | 6.04x |
| 2026-04-15 | 6.16x |
| 2026-04-14 | 6.21x |
| 2026-04-13 | 6.20x |
| 2026-04-10 | 6.16x |
| 2026-04-09 | 6.13x |
| 2026-04-08 | 6.21x |
| 2026-04-07 | 6.08x |
| 2026-04-06 | 6.05x |
| 2026-04-02 | 6.03x |
| 2026-04-01 | 5.99x |
| 2026-03-31 | 6.04x |
| 2026-03-30 | 5.92x |
| 2026-03-27 | 5.93x |
| 2026-03-26 | 5.98x |
| 2026-03-25 | 6.09x |
| 2026-03-24 | 6.14x |
| 2026-03-23 | 6.13x |
| 2026-03-20 | 6.08x |
| 2026-03-19 | 6.12x |
| 2026-03-18 | 6.13x |
| 2026-03-17 | 6.28x |
| 2026-03-16 | 6.20x |
| 2026-03-13 | 6.21x |
| 2026-03-12 | 6.25x |
| 2026-03-11 | 6.46x |
| 2026-03-10 | 6.65x |
| 2026-03-09 | 6.81x |
| 2026-03-06 | 6.81x |
| 2026-03-05 | 6.88x |
| 2026-03-04 | 6.98x |
| 2026-03-03 | 6.96x |
| 2026-03-02 | 6.93x |
| 2026-02-27 | 6.90x |
| 2026-02-26 | 6.93x |
| 2026-02-25 | 6.80x |
| 2026-02-24 | 6.78x |
| 2026-02-23 | 7.03x |
| 2026-02-20 | 6.98x |
| 2026-02-19 | 6.90x |
| 2026-02-18 | 6.98x |
| 2026-02-17 | 6.89x |
| 2026-02-13 | 6.80x |
| 2026-02-12 | 6.62x |
| 2026-02-11 | 6.99x |
| 2026-02-10 | 7.10x |
| 2026-02-09 | 7.44x |
| 2026-02-06 | 7.32x |
| 2026-02-05 | 7.20x |
| 2026-02-04 | 7.09x |
| 2026-02-03 | 6.77x |
| 2026-02-02 | 6.86x |
| 2026-01-30 | 6.96x |
| 2026-01-29 | 6.94x |
| 2026-01-28 | 7.11x |
| 2026-01-27 | 7.04x |
| 2026-01-26 | 7.04x |
| 2026-01-23 | 6.96x |
| 2026-01-22 | 7.04x |
| 2026-01-21 | 7.15x |
| 2026-01-20 | 6.98x |
| 2026-01-16 | 7.10x |
| 2026-01-15 | 7.19x |
| 2026-01-14 | 7.16x |
| 2026-01-13 | 7.02x |
| 2026-01-12 | 7.11x |
| 2026-01-09 | 6.96x |
| 2026-01-08 | 6.92x |
| 2026-01-07 | 6.84x |
| 2026-01-06 | 6.87x |
| 2026-01-05 | 6.76x |
| 2026-01-02 | 6.74x |
| 2025-12-31 | 6.63x |
| 2025-12-30 | 6.70x |
| 2025-12-29 | 6.69x |
| 2025-12-26 | 6.74x |
| 2025-12-24 | 6.73x |
| 2025-12-23 | 6.74x |
| 2025-12-22 | 6.80x |
| 2025-12-19 | 6.75x |
| 2025-12-18 | 6.68x |
| 2025-12-17 | 6.78x |
| 2025-12-16 | 6.82x |
| 2025-12-15 | 6.98x |
| 2025-12-12 | 6.95x |
| 2025-12-11 | 6.96x |
| 2025-12-10 | 6.93x |
| 2025-12-09 | 6.79x |
| 2025-12-08 | 6.89x |
| 2025-12-05 | 7.07x |
| 2025-12-04 | 6.93x |
| 2025-12-03 | 6.93x |
| 2025-12-02 | 6.91x |
| 2025-12-01 | 6.84x |
| 2025-11-28 | 7.05x |
| 2025-11-26 | 7.03x |
| 2025-11-25 | 7.05x |
| 2025-11-24 | 6.90x |
| 2025-11-21 | 6.91x |
| 2025-11-20 | 6.72x |
| 2025-11-19 | 6.75x |
| 2025-11-18 | 6.78x |
| 2025-11-17 | 6.74x |
| 2025-11-14 | 6.73x |
| 2025-11-13 | 6.95x |
| 2025-11-12 | 6.97x |
| 2025-11-11 | 6.96x |
| 2025-11-10 | 6.89x |
| 2025-11-07 | 6.93x |
| 2025-11-06 | 6.88x |
| 2025-11-05 | 6.76x |
| 2025-11-04 | 6.79x |
| 2025-11-03 | 6.86x |
| 2025-10-31 | 6.80x |
| 2025-10-30 | 6.95x |
| 2025-10-29 | 7.18x |
| 2025-10-28 | 7.26x |
| 2025-10-27 | 7.34x |
| 2025-10-24 | 7.34x |
| 2025-10-23 | 7.51x |
| 2025-10-22 | 7.54x |
| 2025-10-21 | 7.59x |
| 2025-10-20 | 7.69x |
| 2025-10-17 | 7.59x |
| 2025-10-16 | 7.64x |
| 2025-10-15 | 7.64x |
| 2025-10-14 | 7.65x |
| 2025-10-13 | 7.73x |
| 2025-10-10 | 7.70x |
| 2025-10-09 | 7.87x |
| 2025-10-08 | 8.00x |
| 2025-10-07 | 8.02x |
| 2025-10-06 | 7.97x |
| 2025-10-03 | 7.89x |
| 2025-10-02 | 7.83x |
| 2025-10-01 | 7.67x |
| 2025-09-30 | 7.75x |
| 2025-09-29 | 7.67x |
| 2025-09-26 | 7.65x |
| 2025-09-25 | 7.57x |
| 2025-09-24 | 7.76x |
| 2025-09-23 | 7.81x |
| 2025-09-22 | 7.77x |
| 2025-09-19 | 7.74x |
| 2025-09-18 | 7.74x |
| 2025-09-17 | 7.69x |
| 2025-09-16 | 7.72x |
| 2025-09-15 | 7.68x |
| 2025-09-12 | 7.65x |
| 2025-09-11 | 7.78x |
| 2025-09-10 | 7.66x |
| 2025-09-09 | 7.91x |
| 2025-09-08 | 7.92x |
| 2025-09-05 | 7.85x |
| 2025-09-04 | 7.75x |
| 2025-09-03 | 7.62x |
| 2025-09-02 | 7.67x |
| 2025-08-29 | 7.77x |
| 2025-08-28 | 7.80x |
| 2025-08-27 | 7.99x |
| 2025-08-26 | 8.08x |
| 2025-08-25 | 8.10x |
| 2025-08-22 | 8.32x |
| 2025-08-21 | 8.17x |
| 2025-08-20 | 8.19x |
| 2025-08-19 | 8.10x |
| 2025-08-18 | 8.11x |
| 2025-08-15 | 8.07x |
| 2025-08-14 | 8.07x |
| 2025-08-13 | 8.17x |
| 2025-08-12 | 8.02x |
| 2025-08-11 | 8.05x |
| 2025-08-08 | 8.04x |
| 2025-08-07 | 7.94x |
| 2025-08-06 | 8.20x |
| 2025-08-05 | 8.34x |
| 2025-08-04 | 8.53x |
| 2025-08-01 | 8.17x |
| 2025-07-31 | 7.95x |
| 2025-07-30 | 8.12x |
| 2025-07-29 | 8.12x |
| 2025-07-28 | 8.00x |
| 2025-07-25 | 8.05x |
| 2025-07-24 | 8.00x |
| 2025-07-23 | 8.00x |
| 2025-07-22 | 7.82x |
| 2025-07-21 | 7.64x |
| 2025-07-18 | 7.54x |
| 2025-07-17 | 7.50x |
| 2025-07-16 | 7.44x |
| 2025-07-15 | 7.37x |
| 2025-07-14 | 7.43x |
| 2025-07-11 | 7.44x |
| 2025-07-10 | 7.55x |
| 2025-07-09 | 7.49x |
| 2025-07-08 | 7.50x |
| 2025-07-07 | 7.50x |
| 2025-07-03 | 7.51x |
| 2025-07-02 | 7.48x |
| 2025-07-01 | 7.49x |
| 2025-06-30 | 7.55x |
| 2025-06-27 | 7.46x |
| 2025-06-26 | 7.49x |
| 2025-06-25 | 7.54x |
| 2025-06-24 | 7.48x |
| 2025-06-23 | 7.44x |
| 2025-06-20 | 7.42x |
| 2025-06-18 | 7.34x |
| 2025-06-17 | 7.31x |
| 2025-06-16 | 7.36x |
| 2025-06-13 | 7.29x |
| 2025-06-12 | 7.38x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael J. Farrell